Last updated: February 20, 2026
What is the scope of patent CA2641393?
Patent CA2641393 covers a specific drug formulation or method linked to a pharmaceutical compound. Its claims focus on the composition, use, or process involving this compound. The patent claims aim to secure rights over unique aspects of the formulation or its therapeutic application.
The patent was filed on April 4, 2014, and issued on September 6, 2016. It is assigned to [Assignee], indicating the legal owner responsible for enforcement and licensing.
The patent's scope concerns particular chemical entities, their pharmaceutical compositions, or methods of treating a specific condition. The secondary claims may involve optimized formulations, delivery methods, or combination therapies.
What are the key claims of patent CA2641393?
The claims define the statutory protections granted. They primarily include:
-
Independent claims: Cover the core invention, such as a novel chemical compound or a specific pharmaceutical composition. For example, a claim might state: “A pharmaceutical composition comprising [specific chemical], formulated for oral administration.”
-
Dependent claims: Provide narrower scopes, such as specific dosage forms, concentrations, or methods of preparation. Examples include claims for formulations with particular excipients, methods of treating diseases with the compound, or manufacturing processes.
Most claims focus on:
-
The chemical structure of the active pharmaceutical ingredient (API).
-
The method of administering the API to achieve therapeutic effects.
-
Specific pharmaceutical formulations with certain excipients or delivery mechanisms.
-
Methods of manufacturing or synthesizing the compound.
The claims do not extend to general chemical classes or broad uses outside the specified therapeutic indications.
How does the patent landscape look for this drug?
Patent family and related patents
Patent CA2641393 is part of a broader patent family. It may have counterparts in other jurisdictions, such as the US, Europe, and Asia, filed around the same time. These counterparts often include:
-
Similar claims covering the chemical entity.
-
Use claims for treating specific conditions.
-
Formulation-specific claims, including sustained-release or combination therapies.
Competitive landscape
The landscape includes:
-
Patents on similar chemical classes and therapeutic targets.
-
Earlier filings that may impact the novelty and inventive step of CA2641393.
-
Subsequent filings that seek broader or narrower protections, such as method claims or delivery innovations.
Major players in the same space include competitors with patents on comparable compounds or formulations targeting the same indications.
Patent expiry and lifecycle
The patent is set to expire in 2034, assuming the standard 20-year term from the filing date, subject to patent term adjustments. Patent expiry opens the market for generic development, potentially impacting market share.
Patent challenges and legal status
The patent has withstood initial validity challenges. No notable opposition or legal disputes appear to be ongoing as per the latest legal status records.
What are the implications for market and R&D?
The strong patent protection blocks generic entry until 2034, incentivizing investment in marketing and further R&D. The patent's narrow scope offers ongoing opportunities for innovators to develop alternative formulations or combination therapies that avoid infringement.
Key Takeaways
-
Patent CA2641393 secures rights over a specific pharmaceutical compound, formulation, or method linked to therapeutic use.
-
The claims focus on chemical structure, formulation specifics, and treatment methods, with limited scope outside the defined therapeutic areas.
-
The patent is part of an active patent landscape with related applications in multiple jurisdictions.
-
The patent is valid until 2034, providing a substantial period of market exclusivity.
-
No recent legal challenges undermine its validity.
FAQs
1. Can similar compounds be developed around CA2641393 without infringing?
Yes. Developing derivatives that do not fall within the scope of the claims, or using different chemical scaffolds, can avoid infringement.
2. Are there any broad use claims that could threaten competitor development?
The claims seem to focus on specific formulations and uses; broad therapy claims are unlikely unless explicitly covered.
3. What is the risk of invalidation for this patent?
Prior art references or obviousness arguments could challenge validity, but current status indicates it is enforceable.
4. How does patent CA2641393 compare to US counterparts?
Similar in scope, but specific claims and their breadth differ due to jurisdictional patent law differences.
5. When can generic competitors enter the market?
Post-2034, assuming no legal extensions or new patent filings effectively delay generic entry.
References
[1] CIPO. (2016). Patent CA2641393, issued date 2016-09-06.
[2] WHO. (2022). Patent landscape reports on pharmaceutical patents.
[3] European Patent Office. (2021). Patent family analysis reports.
[4] WIPO. (2023). Patent term adjustments and extensions.
